Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV

Trikafta sales bolster Vertex’s revenue
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor brought in during its first 10 weeks. For the quarter, Vertex reported non-GAAP EPS of $1.70 on revenues of $1.4 billion, surpassing 4Q18's EPS of $1.30 and revenues of $868 million. The Street was expecting EPS of $1.21 on $1 billion in revenue. Vertex guided to total product revenues of $5.1-$5.3 billion for 2020.

Black Diamond aces NASDAQ debut ...